SCHEMBL31465468

SCHEMBL31465468

CCCCCCc1ncc2c(n1)[nH]c(=O)n2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 1/20 0.41
▸ PDE2A O00408 6/20 0.40
▸ PDE3B Q13370 6/20 0.40
▸ PDE3A Q14432 6/20 0.40
▸ USP2 O75604 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ KEAP1 Q14145 1/20 0.39
▸ NFE2L2 Q16236 1/20 0.39
▸ TLR7 Q9NYK1 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ P2RY12 Q9H244 2/20 0.37
▸ ADORA3 P0DMS8 1/20 0.36
▸ PDE4A P27815 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10006551 0.74 DUT (0.44) PDE2APDE3BPDE3AHPGDP2RY12
SCHEMBL30099906 0.72 GPR84 (0.44) XDHGPR84
SCHEMBL2431484 0.71 TYRO3 (0.49) XDHPDE3BPDE3AP2RY12GPR84
SCHEMBL10006861 0.70 PDE3B (0.47) PDE2APDE3BPDE3AMEN1KMT2A
SCHEMBL12830376 0.70 PDE3B (0.47) PDE2APDE3BPDE3AMEN1KMT2A
SCHEMBL18759700 0.69 MAPT (0.35) XDHHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4566029 0.69 XDH (0.41) XDHPKMHPGDGPR84
SCHEMBL3260370 0.67 XDH (0.39) XDHADORA3ADORA2AGPR84
SCHEMBL30642609 0.66 GPR84 (0.37) XDHGPR84
SCHEMBL10553318 0.65 KMT2A (0.56) MEN1KMT2AMAPTPKMGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049253-A1 BRIDGED CYCLE‑BASED INHIBITORS OF DNA‑DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING JUNO THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
Send feedback